{
  "generated_at": "2026-02-01T15:25:32.713181",
  "days_searched": 3,
  "total_trials": 4,
  "trials": [
    {
      "trial_id": "9f5db5c646c0",
      "title": "RENOVATE-COMPLEX-PCI: Intravascular Imaging vs Angiography-Guided PCI",
      "source": "JACC",
      "source_url": "https://www.jacc.org/doi/10.1016/j.jacc.2023.example",
      "publication_date": "2026-01-30",
      "category": "interventional",
      "summary": "Intravascular imaging (IVUS/OCT) significantly reduced major adverse cardiac events compared to angiography-guided PCI in complex lesions.",
      "key_findings": [
        "Primary endpoint (MACE at 2yr): 7.7% imaging vs 12.3% angiography (HR 0.64, p<0.001)",
        "Target vessel failure reduced by 36%",
        "Stent thrombosis lower with imaging guidance (0.4% vs 1.2%)"
      ],
      "pros": [
        "Robust RCT design with adequate power",
        "Clinically meaningful endpoints",
        "Cost-effectiveness analysis included"
      ],
      "cons": [
        "Open-label design may introduce bias",
        "Expertise-dependent results may not generalize",
        "Additional procedural time and cost"
      ],
      "population": "3,011 patients with complex coronary lesions",
      "intervention": "IVUS or OCT-guided PCI",
      "comparator": "Angiography-guided PCI alone",
      "primary_endpoint": "MACE at 2 years (cardiac death, MI, TVR)",
      "primary_result": "Imaging guidance reduces MACE by 36% in complex PCI",
      "tweet_single": "ðŸ”¬ RENOVATE-COMPLEX: Primary endpoint (MACE at 2yr): 7.7% imaging vs 12.3% angiography (HR 0.64, p<0.001)\n#CardioTwitter #MedTwitter",
      "tweet_thread": [
        "ðŸ§µ NEW: RENOVATE-COMPLEX trial results are out!\n\nIntravascular imaging (IVUS/OCT) significantly reduced major adverse cardiac events compared to angiography-guided PCI in complex lesions.\n\nA thread ðŸ‘‡",
        "ðŸ“Š Study Design:\n\nðŸ‘¥ Population: 3,011 patients with complex coronary lesions\nðŸ’Š Intervention: IVUS or OCT-guided PCI\nðŸ†š Comparator: Angiography-guided PCI alone\nðŸŽ¯ Primary endpoint: MACE at 2 years (cardiac death, MI, TVR)",
        "ðŸ“ˆ Key Findings:\n\n1. Primary endpoint (MACE at 2yr): 7.7% imaging vs 12.3% angiography (HR 0.64, p<0.001)\n2. Target vessel failure reduced by 36%\n3. Stent thrombosis lower with imaging guidance (0.4% vs 1.2%)\n",
        "âš–ï¸ Pros & Cons:\n\nâœ… Robust RCT design with adequate power\nâœ… Clinically meaningful endpoints\n\nâš ï¸ Open-label design may introduce bias\nâš ï¸ Expertise-dependent results may not generalize",
        "ðŸ’¡ Bottom Line: Imaging guidance reduces MACE by 36% in complex PCI\n\nðŸ”— https://www.jacc.org/doi/10.1016/j.jacc.2023.example\n\n#CardioTwitter #MedTwitter #InterventionalCardiology #PCI"
      ],
      "twitter_discussions": [],
      "expert_opinions": [],
      "hashtags": [
        "#CardioTwitter",
        "#MedTwitter",
        "#InterventionalCardiology",
        "#PCI"
      ],
      "fetched_at": "2026-02-01T15:25:32.713075"
    },
    {
      "trial_id": "e76da69e4fe3",
      "title": "TRISCEND-II: Transcatheter Tricuspid Valve Replacement",
      "source": "NEJM",
      "source_url": "https://www.nejm.org/doi/full/10.1056/example",
      "publication_date": "2026-01-29",
      "category": "structural_heart",
      "summary": "First RCT showing transcatheter tricuspid valve replacement superior to medical therapy in severe symptomatic TR.",
      "key_findings": [
        "Primary composite endpoint met: 55% vs 32% improvement (p<0.001)",
        "TR reduction to mild or less: 89% in device group",
        "Quality of life (KCCQ) improved by 22 points vs 5 points",
        "6-minute walk distance improved by 45m vs 12m"
      ],
      "pros": [
        "First RCT in transcatheter tricuspid intervention",
        "Meaningful QoL improvements",
        "Durable TR reduction at 1 year"
      ],
      "cons": [
        "Small sample size (350 patients)",
        "Short follow-up (1 year)",
        "Device-specific results (single valve system)",
        "30-day mortality 2.8%"
      ],
      "population": "350 patients with severe symptomatic TR",
      "intervention": "Transcatheter tricuspid valve replacement (EVOQUE system)",
      "comparator": "Optimal medical therapy",
      "primary_endpoint": "Composite of death, HF hospitalization, or TR improvement",
      "primary_result": "TTVR shows significant benefit over medical therapy for severe TR",
      "tweet_single": "ðŸ”¬ TRISCEND-II: Primary composite endpoint met: 55% vs 32% improvement (p<0.001)\n#CardioTwitter #MedTwitter",
      "tweet_thread": [
        "ðŸ§µ NEW: TRISCEND-II trial results are out!\n\nFirst RCT showing transcatheter tricuspid valve replacement superior to medical therapy in severe symptomatic TR.\n\nA thread ðŸ‘‡",
        "ðŸ“Š Study Design:\n\nðŸ‘¥ Population: 350 patients with severe symptomatic TR\nðŸ’Š Intervention: Transcatheter tricuspid valve replacement (EVOQUE system)\nðŸ†š Comparator: Optimal medical therapy\nðŸŽ¯ Primary endpoint: Composite of death, HF hospitalization, or TR improvement",
        "ðŸ“ˆ Key Findings:\n\n1. Primary composite endpoint met: 55% vs 32% improvement (p<0.001)\n2. TR reduction to mild or less: 89% in device group\n3. Quality of life (KCCQ) improved by 22 points vs 5 points\n",
        "âš–ï¸ Pros & Cons:\n\nâœ… First RCT in transcatheter tricuspid intervention\nâœ… Meaningful QoL improvements\n\nâš ï¸ Small sample size (350 patients)\nâš ï¸ Short follow-up (1 year)",
        "ðŸ’¡ Bottom Line: TTVR shows significant benefit over medical therapy for severe TR\n\nðŸ”— https://www.nejm.org/doi/full/10.1056/example\n\n#CardioTwitter #MedTwitter #StructuralHeart #TAVR"
      ],
      "twitter_discussions": [],
      "expert_opinions": [],
      "hashtags": [
        "#CardioTwitter",
        "#MedTwitter",
        "#StructuralHeart",
        "#TAVR"
      ],
      "fetched_at": "2026-02-01T15:25:32.713140"
    },
    {
      "trial_id": "54123fffc632",
      "title": "SUMMIT-HFpEF: Tirzepatide in HFpEF with Obesity",
      "source": "Circulation",
      "source_url": "https://www.ahajournals.org/doi/10.1161/example",
      "publication_date": "2026-01-31",
      "category": "heart_failure",
      "summary": "Tirzepatide dramatically improved outcomes in HFpEF patients with obesity, marking a new treatment paradigm.",
      "key_findings": [
        "Primary endpoint: 38% reduction in HF worsening events",
        "KCCQ-CSS improved by 19.5 points vs placebo",
        "6MWD increased by 40m vs 5m in placebo",
        "Mean weight loss: 15.7% vs 2.1%"
      ],
      "pros": [
        "Large, well-powered RCT (n=731)",
        "Addresses major unmet need in HFpEF",
        "Dual benefit: HF and metabolic outcomes",
        "Consistent across subgroups"
      ],
      "cons": [
        "GI side effects common (25% nausea)",
        "Cost and access concerns",
        "Unclear if benefit persists off drug",
        "Excluded severe kidney disease"
      ],
      "population": "731 HFpEF patients with BMI â‰¥30",
      "intervention": "Tirzepatide (escalating to max 15mg weekly)",
      "comparator": "Placebo",
      "primary_endpoint": "Composite of CV death or worsening HF events",
      "primary_result": "Tirzepatide is a game-changer for HFpEF with obesity",
      "tweet_single": "ðŸ”¬ SUMMIT: Primary endpoint: 38% reduction in HF worsening events\n#CardioTwitter #MedTwitter",
      "tweet_thread": [
        "ðŸ§µ NEW: SUMMIT trial results are out!\n\nTirzepatide dramatically improved outcomes in HFpEF patients with obesity, marking a new treatment paradigm.\n\nA thread ðŸ‘‡",
        "ðŸ“Š Study Design:\n\nðŸ‘¥ Population: 731 HFpEF patients with BMI â‰¥30\nðŸ’Š Intervention: Tirzepatide (escalating to max 15mg weekly)\nðŸ†š Comparator: Placebo\nðŸŽ¯ Primary endpoint: Composite of CV death or worsening HF events",
        "ðŸ“ˆ Key Findings:\n\n1. Primary endpoint: 38% reduction in HF worsening events\n2. KCCQ-CSS improved by 19.5 points vs placebo\n3. 6MWD increased by 40m vs 5m in placebo\n",
        "âš–ï¸ Pros & Cons:\n\nâœ… Large, well-powered RCT (n=731)\nâœ… Addresses major unmet need in HFpEF\n\nâš ï¸ GI side effects common (25% nausea)\nâš ï¸ Cost and access concerns",
        "ðŸ’¡ Bottom Line: Tirzepatide is a game-changer for HFpEF with obesity\n\nðŸ”— https://www.ahajournals.org/doi/10.1161/example\n\n#CardioTwitter #MedTwitter #HeartFailure #HF"
      ],
      "twitter_discussions": [],
      "expert_opinions": [],
      "hashtags": [
        "#CardioTwitter",
        "#MedTwitter",
        "#HeartFailure",
        "#HF"
      ],
      "fetched_at": "2026-02-01T15:25:32.713158"
    },
    {
      "trial_id": "333f40eb1dae",
      "title": "BEST-CLI 2-Year: Best Endovascular vs Surgical Treatment for CLTI",
      "source": "JACC",
      "source_url": "https://www.jacc.org/doi/10.1016/j.jacc.2024.example",
      "publication_date": "2026-01-28",
      "category": "peripheral",
      "summary": "2-year follow-up confirms surgical bypass superiority over endovascular therapy for CLTI when adequate saphenous vein is available.",
      "key_findings": [
        "MALE/POD: 42% endo vs 32% surgery in good-vein cohort (p=0.008)",
        "Amputation-free survival favored surgery: 72% vs 64%",
        "Reintervention rates 2x higher with endovascular approach",
        "No difference when no adequate vein available"
      ],
      "pros": [
        "Largest CLTI RCT to date (1,830 patients)",
        "Stratified by vein availability (pragmatic)",
        "Long-term follow-up continuing"
      ],
      "cons": [
        "Surgical expertise variability",
        "Endovascular techniques rapidly evolving",
        "High crossover rate (12%)"
      ],
      "population": "1,830 patients with CLTI",
      "intervention": "Surgical bypass",
      "comparator": "Endovascular revascularization",
      "primary_endpoint": "MALE or perioperative death",
      "primary_result": "Surgery beats endovascular for CLTI when good vein available",
      "tweet_single": "ðŸ”¬ BEST-CLI: MALE/POD: 42% endo vs 32% surgery in good-vein cohort (p=0.008)\n#CardioTwitter #MedTwitter",
      "tweet_thread": [
        "ðŸ§µ NEW: BEST-CLI trial results are out!\n\n2-year follow-up confirms surgical bypass superiority over endovascular therapy for CLTI when adequate saphenous vein is available.\n\nA thread ðŸ‘‡",
        "ðŸ“Š Study Design:\n\nðŸ‘¥ Population: 1,830 patients with CLTI\nðŸ’Š Intervention: Surgical bypass\nðŸ†š Comparator: Endovascular revascularization\nðŸŽ¯ Primary endpoint: MALE or perioperative death",
        "ðŸ“ˆ Key Findings:\n\n1. MALE/POD: 42% endo vs 32% surgery in good-vein cohort (p=0.008)\n2. Amputation-free survival favored surgery: 72% vs 64%\n3. Reintervention rates 2x higher with endovascular approach\n",
        "âš–ï¸ Pros & Cons:\n\nâœ… Largest CLTI RCT to date (1,830 patients)\nâœ… Stratified by vein availability (pragmatic)\n\nâš ï¸ Surgical expertise variability\nâš ï¸ Endovascular techniques rapidly evolving",
        "ðŸ’¡ Bottom Line: Surgery beats endovascular for CLTI when good vein available\n\nðŸ”— https://www.jacc.org/doi/10.1016/j.jacc.2024.example\n\n#CardioTwitter #MedTwitter #PAD #VascularMedicine"
      ],
      "twitter_discussions": [],
      "expert_opinions": [],
      "hashtags": [
        "#CardioTwitter",
        "#MedTwitter",
        "#PAD",
        "#VascularMedicine"
      ],
      "fetched_at": "2026-02-01T15:25:32.713172"
    }
  ],
  "search_queries_used": [
    {
      "category": "interventional",
      "term": "PCI randomized trial",
      "query": "PCI randomized trial clinical trial results"
    },
    {
      "category": "interventional",
      "term": "CTO intervention trial",
      "query": "CTO intervention trial clinical trial results"
    },
    {
      "category": "interventional",
      "term": "coronary stent trial",
      "query": "coronary stent trial clinical trial results"
    },
    {
      "category": "interventional",
      "term": "drug-eluting stent trial",
      "query": "drug-eluting stent trial clinical trial results"
    },
    {
      "category": "interventional",
      "term": "IVUS OCT guided PCI",
      "query": "IVUS OCT guided PCI clinical trial results"
    }
  ]
}